Blueprint Medicines Corp
NASDAQ:BPMC
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
73.17
120.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Blueprint Medicines Corp
Blueprint Medicines Corp
Cash Equivalents
Blueprint Medicines Corp
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Blueprint Medicines Corp
NASDAQ:BPMC
|
Cash Equivalents
$54.8m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash Equivalents
$7.3B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Equivalents
$5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Equivalents
$9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Equivalents
$6.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Equivalents
$2B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
Blueprint Medicines Corp
Glance View
In the demanding world of biotechnology, Blueprint Medicines Corp stands out as an influential player, steering the course of precision therapy through innovation. Founded by a team of forward-thinking scientists, the company is deeply entrenched in the pursuit of novel treatments targeting rare genetic diseases and cancers driven by specific genomic alterations. Leveraging its proprietary compound library and a research-centric approach, Blueprint Medicines develops small-molecule kinase inhibitors designed to selectively modulate growth and survival signals in cells. The company’s strategic focus on genomically defined indications allows it to address unmet medical needs, thereby creating substantial value through focused research and rapid clinical advancements. The financial backbone of Blueprint Medicines is built upon a well-rounded strategy encompassing both in-house drug development and strategic collaborations. As the company shepherds its proprietary drugs through the rigorous phases of clinical trials, it also engages in valuable partnerships with pharmaceutical giants to bolster its research capabilities and market reach. With approval and commercialization of therapies like Ayvakit for certain forms of gastrointestinal stromal tumors, Blueprint Medicines generates substantial revenue. These gains are further compounded by milestone payments and royalties from collaborations, all while maintaining a robust pipeline to ensure continued innovation and future income streams. In this way, Blueprint marries scientific rigor with strategic acumen, carving out a sustainable and impactful presence in the biopharmaceutical landscape.
See Also
What is Blueprint Medicines Corp's Cash Equivalents?
Cash Equivalents
54.8m
USD
Based on the financial report for Sep 30, 2024, Blueprint Medicines Corp's Cash Equivalents amounts to 54.8m USD.
What is Blueprint Medicines Corp's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-9%
Over the last year, the Cash Equivalents growth was -2%. The average annual Cash Equivalents growth rates for Blueprint Medicines Corp have been -54% over the past three years , -9% over the past five years .
You don't have any saved screeners yet
